The CARRA Registry was created to monitor the long term safety of the medications used to treat pediatric rheumatic diseases. A recent survey of caregivers of children with rheumatic diseases listed understanding long term safety of medications as their #1 priority. But the registry does so much more: It also collects large amounts of information on thousands of patients, their treatments, side effects and quality of life, so you will be able to make more informed decisions about your/your child’s health. The goal is to have all the information you need to choose the safest treatment for your desired outcome.
The CARRA Registry is a database of information collected about children and young adults with pediatric-onset rheumatic diseases such as juvenile idiopathic arthritis (JIA), lupus and juvenile dermatomyositis (JDM). Patient families from all over North America can join the CARRA Registry. A map of clinics who enroll for the registry can be found below. Information collected by the CARRA Registry includes:
The securely stored identity protected information is then shared with CARRA members to better understand pediatric rheumatic diseases. The CARRA Registry will be expanding to add juvenile scleroderma soon!
Pediatric rheumatic diseases are life-long. We often don’t know what happens to the child’s disease after they transition to an adult doctor. The CARRA Registry collects information for at least 10 years and includes ways of collecting information from young adults no longer under the care of a pediatric rheumatologist.
Patient Families and CARRA members create a CARRA Registry Newsletter. The newsletter contains more information about the Registry and CARRA research studies.
To learn more about the CARRA Registry and see some Frequently Asked Questions, please click on the CARRA Registry Brochure below.
For additional Registry questions, please contact our Director of Strategic Partnerships & Patient Engagement, Vincent Del Gaizo, at [email protected].